Clinical Trials Browser

Carcinoma, Neuroendocrine × Octreotide × Clear all

NCT01121939 2016-02-05

Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers

Phase 2 Completed

43 enrolled 9 charts

Carcinoma, Neuroendocrine